U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07466602) titled 'cfDNA Methylation for Liver Cancer Recurrence Detection' on Feb. 26.
Brief Summary: Through follow-up testing of patients with primary liver cancer who underwent hepatectomy, liver transplantation, ablation therapy, or transarterial chemoembolization (TACE), a blinded comparative trial was conducted at each monitoring site. This trial evaluated the combined methylation detection kit for GNB4 and Riplet genes (fluorescent PCR method) against the clinical reference standard (defined as the physician's comprehensive diagnosis based on clinical guidelines and other criteria). The study evaluated the clinical performance of the assay in...